[Vitamin D therapy in renal osteodystrophy].

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Renal osteodystrophy is a common complication of chronic kidney disease.
• Secondary hyperparathyroidism is a hallmark of renal osteodystrophy.
• Vitamin D therapy is crucial for managing renal osteodystrophy.

Purpose of the Study:

• To review available vitamin D preparations for renal osteodystrophy in Japan.
• To outline therapeutic strategies for secondary hyperparathyroidism.
• To emphasize safety parameters for vitamin D therapy.

Main Methods:

• Review of currently available oral and intravenous vitamin D preparations in Japan.
• Discussion of treatment indications for mild, moderate, and severe secondary hyperparathyroidism.
• Highlighting the importance of monitoring serum intact PTH and Ca/P product.

Main Results:

• Three oral (calcitriol, alfacalcidol, falecalcitriol) and two intravenous (calcitriol, maxacalcitol) preparations are available.
• Oral therapy is generally for mild cases (intact PTH <300 pg/mL), with pulse therapy for moderate to severe cases.
• Intravenous therapy offers rapid clearance for more severe cases.

Conclusions:

• Safe and effective vitamin D therapy for renal osteodystrophy necessitates maintaining serum intact PTH (150-300 pg/mL) and Ca/P product (<55).
• These parameters help prevent adynamic bone and vascular calcification.
• Understanding the nuances of oral and intravenous vitamin D preparations is key for optimal patient outcomes.